Hill-Rom Holdings, Inc. (NYSE:HRC) Position Reduced by Johnson Investment Counsel Inc.

Johnson Investment Counsel Inc. cut its position in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 1.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 21,638 shares of the medical technology company’s stock after selling 230 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Hill-Rom were worth $2,458,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of HRC. Bedel Financial Consulting Inc. increased its holdings in shares of Hill-Rom by 43.0% in the 2nd quarter. Bedel Financial Consulting Inc. now owns 502 shares of the medical technology company’s stock valued at $57,000 after purchasing an additional 151 shares during the period. Compagnie Lombard Odier SCmA acquired a new position in Hill-Rom in the second quarter worth approximately $62,000. Key Financial Inc acquired a new position in Hill-Rom in the second quarter worth approximately $87,000. Northwestern Mutual Wealth Management Co. increased its holdings in Hill-Rom by 150.5% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 704 shares of the medical technology company’s stock worth $80,000 after buying an additional 423 shares during the last quarter. Finally, Advisory Services Network LLC acquired a new position in Hill-Rom in the second quarter worth approximately $94,000. 84.11% of the stock is owned by institutional investors.

In other Hill-Rom news, SVP Mary Kay Ladone sold 9,056 shares of the stock in a transaction on Wednesday, July 28th. The stock was sold at an average price of $127.62, for a total transaction of $1,155,726.72. Following the completion of the transaction, the senior vice president now directly owns 2,698 shares in the company, valued at $344,318.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.69% of the company’s stock.

HRC has been the topic of a number of research reports. Robert W. Baird downgraded Hill-Rom from an “outperform” rating to a “neutral” rating and increased their price objective for the stock from $150.00 to $156.00 in a report on Friday, September 3rd. Bank of America cut Hill-Rom from a “buy” rating to a “neutral” rating and set a $130.00 target price for the company. in a research report on Tuesday, August 10th. Morgan Stanley cut Hill-Rom from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $148.00 to $156.00 in a research report on Sunday, September 19th. Finally, KeyCorp cut Hill-Rom from an “overweight” rating to a “sector weight” rating in a research report on Wednesday, September 8th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $141.80.

Shares of HRC stock opened at $151.49 on Thursday. The stock has a market cap of $9.97 billion, a P/E ratio of 42.67 and a beta of 0.60. Hill-Rom Holdings, Inc. has a one year low of $86.51 and a one year high of $152.37. The stock has a fifty day moving average price of $144.15 and a 200 day moving average price of $124.98. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.38 and a quick ratio of 1.03.

Hill-Rom (NYSE:HRC) last issued its earnings results on Friday, July 30th. The medical technology company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.35 by $0.03. The firm had revenue of $717.70 million during the quarter, compared to analysts’ expectations of $708.33 million. Hill-Rom had a return on equity of 21.74% and a net margin of 8.12%. Hill-Rom’s quarterly revenue was down 6.5% compared to the same quarter last year. During the same period last year, the business earned $1.95 earnings per share. Equities research analysts anticipate that Hill-Rom Holdings, Inc. will post 6.11 EPS for the current year.

Hill-Rom Profile

Hill-Rom Holdings, Inc operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions.

Featured Story: Dual Listing What You Need to Know

Institutional Ownership by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.